Omani experience with the use of factor IX Fc fusion protein

We describe our local experience in the management of haemophilia B patients with factor IX Fc fusion protein. Two children with haemophilia B were managed with the use of a personalised/tailored dosing schedule of factor IX Fc fusion protein. Compared with the standard half-life factor IX, prophyla...

Descripción completa

Detalles Bibliográficos
Autores principales: Alzadjali, Shireen I, Wali, Yasser
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8296795/
https://www.ncbi.nlm.nih.gov/pubmed/34290003
http://dx.doi.org/10.1136/bcr-2020-241154
_version_ 1783725713279418368
author Alzadjali, Shireen I
Wali, Yasser
author_facet Alzadjali, Shireen I
Wali, Yasser
author_sort Alzadjali, Shireen I
collection PubMed
description We describe our local experience in the management of haemophilia B patients with factor IX Fc fusion protein. Two children with haemophilia B were managed with the use of a personalised/tailored dosing schedule of factor IX Fc fusion protein. Compared with the standard half-life factor IX, prophylaxis with factor IX Fc fusion protein was cost-effective, with much less injections, better bleeding control, improved tolerability or no inhibitor development.
format Online
Article
Text
id pubmed-8296795
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-82967952021-08-12 Omani experience with the use of factor IX Fc fusion protein Alzadjali, Shireen I Wali, Yasser BMJ Case Rep Case Report We describe our local experience in the management of haemophilia B patients with factor IX Fc fusion protein. Two children with haemophilia B were managed with the use of a personalised/tailored dosing schedule of factor IX Fc fusion protein. Compared with the standard half-life factor IX, prophylaxis with factor IX Fc fusion protein was cost-effective, with much less injections, better bleeding control, improved tolerability or no inhibitor development. BMJ Publishing Group 2021-07-21 /pmc/articles/PMC8296795/ /pubmed/34290003 http://dx.doi.org/10.1136/bcr-2020-241154 Text en © BMJ Publishing Group Limited 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Case Report
Alzadjali, Shireen I
Wali, Yasser
Omani experience with the use of factor IX Fc fusion protein
title Omani experience with the use of factor IX Fc fusion protein
title_full Omani experience with the use of factor IX Fc fusion protein
title_fullStr Omani experience with the use of factor IX Fc fusion protein
title_full_unstemmed Omani experience with the use of factor IX Fc fusion protein
title_short Omani experience with the use of factor IX Fc fusion protein
title_sort omani experience with the use of factor ix fc fusion protein
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8296795/
https://www.ncbi.nlm.nih.gov/pubmed/34290003
http://dx.doi.org/10.1136/bcr-2020-241154
work_keys_str_mv AT alzadjalishireeni omaniexperiencewiththeuseoffactorixfcfusionprotein
AT waliyasser omaniexperiencewiththeuseoffactorixfcfusionprotein

Ejemplares similares